Inhaled treprostinil for interstitial lung disease-associated pulmonary hypertension: a silver lining on a very dark cloud

Tweetable abstract

Pulmonary hypertension associated with ILD is a very severe condition. The open label extension of the INCREASE trial demonstrates acceptable tolerability of inhaled treprostinil, maintained exercise capacity at week 40, and increase in FVC.https://bit.ly/3qxHvsB